Invitrogen™ Crenezumab Recombinant Monoclonal Antibody

Beschreibung

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

DLX212 is a biosimilar to anti-human amyloid beta antibodies, specifically designed for research applications such as ELISA and functional assays. DLX212 targets the beta amyloid peptide, with its specificity stemming from its recombinant monoclonal antibody structure, offering researchers a reliable tool in in vivo studies. Its application is strictly within the realm of research, aiding studies focused on amyloid pathologies, primarily Alzheimer's disease. DLX212 serves as an alternative to other anti-beta amyloid antibodies like crenezumab, with its preparation allowing it to be versatile across multiple assay platforms.